GlassScriptPhysician profile
Lawrence H Albert
NPI 1639123359
$3,321.50
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $819 · 2021: $406 · 2022: $727 · 2023: $577 · 2024: $98.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $640.81 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $361.46 | 2019-2023 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.56 | 2019-2023 | |
| Harmony Biosciences LLC | $307.01 | 2020-2023 | Wakix |
| Merck Sharp & Dohme LLC | $196.48 | 2019-2024 | Zerbaxa, Recarbrio, Verquvo |
| Advanced Respiratory, INC | $195.78 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $179.53 | 2019-2024 | Opsumit, Uptravi |
| Abbott Laboratories | $168.23 | 2022 | |
| Philips North America LLC | $140.08 | 2019-2023 | |
| Insmed, INC. | $137.06 | 2019-2023 | Arikayce |
| Mylan Specialty L.P. | $93.25 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $84.47 | 2020-2024 | Nuzyra |
| Jazz Pharmaceuticals INC. | $48.25 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $45.46 | 2022 | |
| Genzyme Corporation | $45.21 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $43.68 | 2020-2022 | |
| Genentech USA, INC. | $42.09 | 2021-2022 | |
| Eisai INC. | $35.73 | 2020-2022 | |
| Shionogi INC | $34.83 | 2023 | Fetroja |
| Amgen INC. | $26.90 | 2022 | |
| Janssen Pharmaceuticals, INC | $26.18 | 2019-2021 | |
| Janssen Biotech, INC. | $22.92 | 2023 | Symtuza |
| Grifols USA, LLC | $21.39 | 2019 | |
| Abbvie INC. | $19.94 | 2022 | |
| Csl Behring | $17.90 | 2019 | |
| Axsome Therapeutics, INC. | $17.75 | 2023 | Sunosi |
| Resmed Corp | $16.31 | 2019 | |
| Chiesi USA, INC. | $16.08 | 2019 | |
| Circassia INC. | $14.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.